QDVG:F:F-iShares S&P 500 Health Care Sector UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 10.676

Change

-0.22 (-2.06)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-14 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

N/A

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

N/A

USD 114.13B
SXR8:F iShares Core S&P 500 UCITS ETF..

N/A

USD 106.46B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.53 (-0.94%)

USD 100.12B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.08 (-0.49%)

USD 63.18B
VUSA:F Vanguard Funds Public Limited ..

-0.42 (-0.38%)

USD 51.63B
VUAA:F Vanguard S&P 500 UCITS Acc

-0.40 (-0.37%)

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

N/A

USD 51.11B
XJSE:F Xtrackers II - Japan Governmen..

-0.10 (-1.28%)

USD 43.12B
0ZC:F Zscaler Inc

-0.62 (-0.34%)

USD 37.92B

ETFs Containing QDVG:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.40% 85% B 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.40% 84% B 68% D+
Trailing 12 Months  
Capital Gain 6.40% 46% F 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.40% 41% F 46% F
Trailing 5 Years  
Capital Gain 54.66% 79% B- 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 54.66% 78% C+ 57% F
Average Annual (5 Year Horizon)  
Capital Gain 12.68% 78% C+ 70% C-
Dividend Return 12.68% 75% C 63% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.97% 63% D 89% A-
Risk Adjusted Return 115.59% 98% N/A 97% N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike